Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | HTR6 | P50406 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CCR5 | P51681 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6008838 | 0.87 | HTR2A (0.56) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5760363 | 0.83 | HTR2A (0.61) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10021777 | 0.80 | HTR2A (0.58) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6008823 | 0.80 | UTS2R (0.61) | HTR2ACCR5 | |
| SCHEMBL6007500 | 0.79 | HTR2A (0.55) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10021778 | 0.79 | KCNH2 (0.54) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14318600 | 0.78 | HTR2A (0.81) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6009365 | 0.78 | HTR2A (0.46) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7310084 | 0.77 | HTR2A (0.63) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10722200 | 0.77 | HTR2A (0.59) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078537-B2 | Phenylalkyl diamine and amide analogs | SK CORPORATION (KR) | 2006-07-18 | — | — | US | claimed |
| US-20030105079-A1 | Novel phenylalkyl diamine and amide analogs | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2003-06-05 | — | — | US | claimed |
| US-7078537-B2 | Phenylalkyl diamine and amide analogs | SK CORPORATION (KR) | 2006-07-18 | — | — | US | disclosed |
| EP-1401821-A4 | NOVEL PHENYLALKYL DIAMINE AND AMIDE ANALOGS | SK CORP (KR) | 2006-05-31 | — | — | EP | disclosed |
| EP-1401821-A1 | NOVEL PHENYLALKYL DIAMINE AND AMIDE ANALOGS | SK Corporation (KR) | 2004-03-31 | — | — | EP | disclosed |
| US-20030105079-A1 | Novel phenylalkyl diamine and amide analogs | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2003-06-05 | — | — | US | disclosed |
| WO-2002100848-A1 | NOVEL PHENYLALKYL DIAMINE AND AMIDE ANALOGS | SK CORPORATION (KR) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105079-A1 | Novel phenylalkyl diamine and amide analogs | SIGMAR1, TAAR1, OPRL1 | HTR2A 58/4885KDM4E 2001/4885CYP1A2 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.